← Leaderboards
Barry J. Byrne
University Of Florida
$9,633,932
Attributed
$13,105,089
Total exposure
21
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,855,032 · 23
By mechanism
P01$6,844,682 · 5
R01$5,304,786 · 2
U42$3,287,148 · 1
UG3$1,657,797 · 1
U01$1,568,525 · 1
P50$489,442 · 1
Top collaborators
- David D Fuller12 shared
- Coy D Heldermon3 shared
Most similar at University Of Florida
Same institution · by research overlap
- David D Fuller$12,096,681
- Mai Elmallah$6,605,741
- Nicholas Muzyczka$10,997,810
- Darin J Falk$1,302,158
- Coy D Heldermon$4,153,336
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyGlycogen Storage Disease Type IiVectorGrantGlycogenGenesImmune ResponseEnzymesProteinsRecombinantsDoseBaseMutationRespiratorySerotypingTissuesResearch PersonnelMuscleGene TransferAcidsAdeno-Associated Viral VectorNeuromuscular DiseasesEnzyme Replacement TherapyDependovirus
Grant awards (58)
Procession to IND of a capsid mutated AAV8 codon optimized NAGLU vector for treatment of Sanfilippo Syndrome type B (Supplement)$538,939
UG3 · FY2025 · NS
Procession to IND of a capsid mutated AAV8 codon optimized NAGLU vector for treatment of Sanfilippo Syndrome type B$535,428
UG3 · FY2025 · NS
Procession to IND of a capsid mutated AAV8 codon optimized NAGLU vector for treatment of Sanfilippo Syndrome type B$583,430
UG3 · FY2024 · NS
Control of Breathing and Pompe Disease$580,911
R01 · FY2024 · HD · contact PI
Control of Breathing and Pompe Disease$593,203
R01 · FY2023 · HD · contact PI
Control of Breathing and Pompe Disease$593,203
R01 · FY2022 · HD · contact PI
Control of Breathing and Pompe Disease$593,203
R01 · FY2021 · HD · contact PI
Control of Breathing and Pompe Disease$615,147
R01 · FY2020 · HD · contact PI
Phase II Study of AAV9-GAA Gene Transfer in Pompe Disease$403,073
U01 · FY2019 · HL · contact PI
Phase II Study of AAV9-GAA Gene Transfer in Pompe Disease$564,323
U01 · FY2017 · HL · contact PI
Control of Breathing and Pompe Disease$380,249
R01 · FY2016 · HD · contact PI
Phase II Study of AAV9-GAA Gene Transfer in Pompe Disease$601,129
U01 · FY2015 · HL · contact PI
Control of Breathing and Pompe Disease$379,343
R01 · FY2015 · HD · contact PI
Control of Breathing and Pompe Disease$383,016
R01 · FY2014 · HD · contact PI
Control of Breathing and Pompe Disease$371,460
R01 · FY2013 · HD · contact PI
Spinal and brainstem respiratory neurons in Pompe disease$179,731
R21 · FY2013 · NS
Vector Core$176,025
P01 · FY2013 · HL · contact PI
Control of Breathing and Pompe Disease$391,551
R01 · FY2012 · HD · contact PI
Spinal and brainstem respiratory neurons in Pompe disease$223,500
R21 · FY2012 · NS
Vector Core$185,698
P01 · FY2012 · HL · contact PI
Vector Core$189,885
P01 · FY2011 · HL · contact PI
Vector Core$190,637
P01 · FY2010 · HL · contact PI
Recombinant AAV for Correction of Genetic Abnormalities$1,118,918
P01 · FY2009 · DK · contact PI
Vector Core$193,937
P01 · FY2009 · HL · contact PI
Strategies for Sustained Effect of AAV-mediated Correction of Pompe Disease$169,025
P01 · FY2009 · DK · contact PI
Recombinant AAV for Correctional Genetic Abnormalities Project 4: Strategies for$43,823
P01 · FY2009 · DK · contact PI
PHASE I TRIAL OF OCULAR SUBRETINAL INJECTION OF A RAAV2-CB - HRPE65$37,408
M01 · FY2009 · RR · contact PI
CARDIAC AND SKELETAL MUSCLE IN BARTH SYNDROME$9,099
M01 · FY2009 · RR · contact PI
AGLU03206 OPEN LABEL EXTENSION OF AGLU02704$2,426
M01 · FY2009 · RR · contact PI
Recombinant AAV for Correction of Genetic Abnormalities$1,050,549
P01 · FY2008 · DK · contact PI
Strategies for Sustained Effect of AAV-mediated Correction of Pompe Disease$158,699
P01 · FY2008 · DK · contact PI
PHASE I TRIAL OF OCULAR SUBRETINAL INJECTION OF A RAAV2-CB - HRPE65$55,823
M01 · FY2008 · RR · contact PI
CARDIAC AND SKELETAL MUSCLE IN BARTH SYNDROME$4,878
M01 · FY2008 · RR · contact PI
AGLU03206 OPEN LABEL EXTENSION OF AGLU02704$4,336
M01 · FY2008 · RR · contact PI
Recombinant AAV for Correction of Genetic Abnormalities$1,249,505
P01 · FY2007 · DK · contact PI
Strategies for Sustained Effect of AAV-mediated Correction of Pompe Disease$310,177
P01 · FY2007 · DK · contact PI
RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE TRMT IN PTS WITH GLYCOGEN STORAGE DIS$7,075
M01 · FY2007 · RR · contact PI
Core--Administrative$1
P01 · FY2007 · DK · contact PI
NGVL TOXICOLOGY LABORATORY$349,184
U42 · FY2006 · RR · contact PI
CORRECTION OF INHERITED CARDIOMYOPATHY USING AAV VECTORS$219,976
P01 · FY2006 · HL · contact PI
Strategies for Sustained Effect of AAV-mediated Correction of Pompe Disease$218,853
P01 · FY2006 · DK · contact PI
RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE TRMT IN PTS WITH GLYCOGEN STORAGE DIS$18,286
M01 · FY2006 · RR · contact PI
(RHGAA) TRMT IN PTS 6 MONTH W/INFANTILE-ONSET POMPE DISEASE$12,774
M01 · FY2006 · RR · contact PI
NGVL TOXICOLOGY LABORATORY$2,937,964
U42 · FY2005 · RR
CORRECTION OF INHERITED CARDIOMYOPATHY USING AAV VECTORS$375,595
P01 · FY2005 · HL
Strategies for Sustained Effect of AAV-mediated Correction of Pompe Disease$210,975
P01 · FY2005 · DK
(RHGAA) TRMT IN PTS U 6 MONTI W/INFANTILE-ONSET POMPE DISEASE$63,728
M01 · FY2005 · RR
RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE TRMT IN PTS WITH GLYCOGEN STORAGE DIS$28,765
M01 · FY2005 · RR
Recombinant Human Acid alpha-Glucosidase trmt in pts with Glycogen Storage Dis$54,823
M01 · FY2004 · RR
CORRECTION OF INHERITED CARDIOMYOPATHY USING AAV VECTORS$219,976
P01 · FY2002 · HL
GENE THERAPY FOR GLYCOGEN STORAGE DISEASE$187,476
P01 · FY2002 · DK
GLYCOGEN STORAGE DISEASE TREATMENT: HEPATIC GENE THERAPY$140,730
R01 · FY2002 · DK
CORRECTION OF INHERITED CARDIOMYOPATHY USING AAV VECTORS$219,976
P50 · FY2001 · HL
GENE THERAPY FOR GLYCOGEN STORAGE DISEASE$187,476
P01 · FY2001 · DK
GLYCOGEN STORAGE DISEASE TREATMENT: HEPATIC GENE THERAPY$141,385
R01 · FY2001 · DK
CORRECTION OF INHERITED CARDIOMYOPATHY USING AAV VECTORS$269,466
P50 · FY2000 · HL
GENE THERAPY FOR GLYCOGEN STORAGE DISEASE$187,476
P01 · FY2000 · DK
GLYCOGEN STORAGE DISEASE TREATMENT: HEPATIC GENE THERAPY$141,385
R01 · FY2000 · DK